This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp (BCT.TO) is seeing a positive trend, closing up 2.28% in the latest trading session. This reflects a growing confidence among investors.
In this session, Briacell's stock rose to CA$4.04, driven by ongoing developments in the biotech sector, especially in immunotherapy.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$42.89M
52W high
$20.40
52W low
$3.68
1W change
-5.01%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 305.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+305.7% Upside
Current Price
C$4.93
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
81.8%
Annualized
90-Day Vol
87.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.89
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.23 | C$3.95 โ C$6.94 |
| 60 trading days | C$5.55 | C$3.73 โ C$8.28 |
| 90 trading days | C$5.89 | C$3.61 โ C$9.61 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Keep an eye on Briacell's progress in immunotherapy, as recent advancements could impact future stock performance.
Briacell Therapeutics Corp Market Cap Reaches CA$33.9 Million
With a market cap of CA$33.9 million, Briacell operates in a specialized area of the biotech industry, focusing on personalized cancer immunotherapies.
Bull case
Briacell's stock rise may be due to increasing investor confidence in its innovative cancer treatments. This boost follows positive clinical results and strategic moves by the company.
Bear case
Even with the recent gains, investors should stay cautious. The biotech sector can be unpredictable, and any setbacks in clinical trials or regulatory approvals could affect stock performance.
Recent Performance Overview
Advertisement
Briacell's stock has shown resilience, with a 2.28% increase in the last session. This positive movement aligns with a broader trend in the biotech sector, where innovative solutions are attracting investor interest.
Market Sentiment and Future Outlook
The market's reaction to Briacell's advancements in personalized immunotherapy is encouraging. Investors are hopeful about future growth, especially as the company continues to make progress in clinical trials and product development. For more details on Briacell's stock performance, visit our BCT.TO page.
Key Developments to Watch
As Briacell moves forward, important developments such as upcoming clinical trial results and corporate announcements will play a crucial role in shaping investor sentiment. Keep an eye on these factors, as they could significantly influence the stock's direction. For ongoing updates, check our Briacell Therapeutics Corp stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
